ERBB2 and breast carcinoma: In terms of Ki-67, values above 30% in the residual tumour was found to be prognostic for lower DFS (HR 3.86, 95% CI 1.19–9.21, p = 0.008) in patients receiving NAC for localised hormone receptor (HR)-HER2-negative or -positive breast cancer (63).